Effects of autologous hematopoietic stem cell transplantation as the first-line consolidation therapy for high-risk diffuse large B-cell lymphoma
10.3760/cma.j.cn115356-20210813-00180
- VernacularTitle:自体造血干细胞移植一线巩固治疗高危弥漫大B细胞淋巴瘤的效果
- Author:
Fangfang YUAN
1
;
Qingsong YIN
;
Jian ZHOU
;
Yufu LI
;
Yuewen FU
;
Yanyan LIU
;
Xudong WEI
;
Yongping SONG
Author Information
1. 郑州大学附属肿瘤医院 河南省肿瘤医院血液科，郑州 450008
- Keywords:
Lymphoma, large B-cell, diffuse;
Hematopoietic stem cell transplantation;
Rituximab
- From:
Journal of Leukemia & Lymphoma
2022;31(3):151-155
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the long-term efficacy of autologous hematopoietic stem cell transplantation (auto-HSCT) as the first-line consolidation therapy for high-risk diffuse large B-cell lymphoma (DLBCL) in the rituximab era.Methods:From January 2010 to June 2017, 113 DLBCL patients admitted to Henan Cancer Hospital who had complete remission (CR) after rituximab combined with chemotherapy were enrolled. Among 113 patients, 40 cases received auto-HSCT as the first-line consolidation treatment after chemotherapy (transplantation group) and 73 cases received chemotherapy only (non-transplantation group). The clinical data of 113 patients were retrospectively analyzed. The overall survival (OS) and progression-free survival (PFS) were analyzed by Kaplan-Meier method, and OS and PFS were compared between both groups.Results:The 2-, 3- and 5-year OS rates of transplantation group and non-transplantation group were 90.0% vs. 91.8%, 84.9% vs. 80.1%, 80.9% vs. 72.8%, respectively, and the difference in OS was statistically significant of both groups ( P = 0.457); the 2-, 3- and 5-year PFS rates were 85.0% vs. 85.0%, 82.2% vs. 61.8%, 82.2% vs. 60.0%, respectively, and the difference in PFS was statistically significant of both groups ( P = 0.046). None of the patients in the transplantation group experienced early transplantation-related death. Conclusions:In the era of rituximab treatment, the first-line auto-HSCT consolidation therapy could improve the PFS of high-risk DLBCL patients who are sensitive to chemotherapy, and it may improve the OS with a good safety.
